We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

34 hedge funds and large institutions have $74.5M invested in Eledon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

7.73% more ownership

Funds ownership: 58.13% → 65.85% (+7.7%)

0% more funds holding

Funds holding: 34 → 34 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

16% less capital invested

Capital invested by funds: $89M → $74.5M (-$14.4M)

Holders
34
Holders Change
–
Holders Change %
0%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
13
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$10.5M
2
Morgan Stanley
Morgan Stanley
New York
+$7.92M
3
IC
Ikarian Capital
Texas
+$943K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$601K
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$568K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$11.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$371K
3
WP
Woodline Partners
California
-$317K
4
Citadel Advisors
Citadel Advisors
Florida
-$268K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$238K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$11.2M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$10.7M – – –
LGM
3
Logos Global Management
California
$10.6M +$10.5M +1,115,722 +498%
BI
4
BVF Inc
California
$8.81M – – –
WP
5
Woodline Partners
California
$6.78M -$317K -33,610 -4%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$6.75M -$371K -39,347 -4%
Morgan Stanley
7
Morgan Stanley
New York
$6.73M +$7.92M +839,403 +7,236%
IC
8
Ikarian Capital
Texas
$2.77M +$943K +100,000 +40%
Janus Henderson Group
9
Janus Henderson Group
United Kingdom
$1.93M +$294K +31,196 +15%
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.66M -$191K -20,294 -9%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$1.49M +$601K +63,690 +51%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$985K +$240K +25,491 +26%
Two Sigma Advisers
13
Two Sigma Advisers
New York
$619K +$568K +60,200 +333%
CM
14
CM Management
Florida
$593K – – –
Two Sigma Investments
15
Two Sigma Investments
New York
$455K +$188K +19,941 +53%
ISL
16
Ingalls & Snyder LLC
New York
$405K – – –
BlackRock
17
BlackRock
New York
$366K +$321K +34,012 +277%
BFM
18
Boothbay Fund Management
New York
$317K +$107K +11,360 +40%
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
$286K – – –
V
20
Veritable
Delaware
$262K +$312K +33,092 New
State Street
21
State Street
Massachusetts
$261K +$311K +32,935 New
Northern Trust
22
Northern Trust
Illinois
$254K +$156K +16,588 +107%
Renaissance Technologies
23
Renaissance Technologies
New York
$167K -$56.1K -5,944 -22%
Millennium Management
24
Millennium Management
New York
$142K +$32.1K +3,405 +23%
Rockefeller Capital Management
25
Rockefeller Capital Management
New York
$13K – – –
1
2

ELDN Hedge Fund Activity: Q2 2021 in Review

34 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2021, worth a combined $74.5M — down 16% from $89M a quarter earlier.

Fund positioning in ELDN was balanced in Q2 2021: 6 funds opened new positions, 6 closed out, 13 added to existing stakes and 7 trimmed.

The largest buyer was Logos Global Management, adding an estimated $10.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $11.9M sold.

  • 34 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2021, unchanged from Q1 2021.
  • Funds reported $74.5M of Eledon Pharmaceuticals stock for Q2 2021, down 16% quarter-over-quarter.
  • 6 funds opened new Eledon Pharmaceuticals positions in Q2 2021 and 6 closed out, a net change of 0 holders.
  • The largest Eledon Pharmaceuticals buyer in Q2 2021 was Logos Global Management, an estimated $10.5M added.
  • The largest Eledon Pharmaceuticals seller in Q2 2021 was EcoR1 Capital, an estimated $11.9M sold.

Based on aggregated 13F filings for Q2 2021.